Knockdown of LMX1B Suppressed Cell Apoptosis and Inflammatory Response in IL-1β-Induced Human Osteoarthritis Chondrocytes through NF-κB and NLRP3 Signal Pathway

Yiping Mu, Lining Wang, Ling Fu, and Qi Li

1Hand Surgery Department, Central Hospital Affiliated to Shenyang Medical College, Shenyang Clinical Research for Hand and Foot Diseases, Shenyang, 110024 Liaoning Province, China
2Laboratory Department, Central Hospital Affiliated to Shenyang Medical College, Shenyang, 110024 Liaoning Province, China

Correspondence should be addressed to Yiping Mu; yiping.mu@symc.edu.cn and Qi Li; liqi_zxw@163.com

Received 12 August 2021; Accepted 8 August 2022; Published 12 September 2022

1. Introduction

Osteoarthritis (OA), a chronic degenerative joint disease, always occurred in the aging population. There is evidence suggests that chondrocytes’ survival, inflammation, and apoptosis play critical roles in OA pathogenesis. LMX1B has been shown to be involved in antiosteogenic function in early patterning of the calvaria. However, the role and mechanism of LMX1B in OA is not unknown. The present study observed that LMX1B was highly expressed in OA patients compared with normal patients. Besides, we found that IL-1β increased LMX1B mRNA and protein expression in SW1353 and C28/I2 chondrocytes. LMX1B knockdown increased IL-1β-induced cell viability and proliferation and suppressed cell apoptosis and inflammation response, including IFN-γ, TNF-α, IL-6, prostaglandin E2 (PGE2), and NO both in SW1353 and C28/I2. Furthermore, LMX1B silence inhibited MMP-3 and MMP-13 expression both in SW1353 and C28/I2 cells. Also, the activation of the NF-κB and NLRP3 signaling pathway was suppressed in LMX1B silence cells by decreasing the p-p65 and NLRP3 protein expressions. Additionally, inhibition of NF-κB by PDTC suppressed NLRP3 expression. Moreover, NLRP3 overexpression reversed the effects of LMX1B silence on chondrocytes’ survival, proliferation, apoptosis, and inflammation. Finally, we confirmed that LMX1B depletion had protective effects in OA rats in vivo.
system, limbs, and kidney [15, 17, 18]. Also, evidence suggested that LMX1B plays important roles in the cell apoptosis inhibition under hypoxia and reoxygenation condition in renal tubular epithelial cells [19]. However, the specific role and molecular mechanism of LMX1B in IL-1β-induced human osteoarthritis chondrocytes are poorly understood.

Nod-like receptor protein 3 (NLRP3) inflammasome, known as innate immune sensors, contains NLRP3 protein, pro-caspase-1, and apoptosis-associated speckle-like protein which is involved in cell apoptosis and inflammation response [20, 21]. There is convincing evidence that the elevation of NLRP3 is closely connected with proinflammatory cytokine production, including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) [22]. Moreover, the nuclear factor-kappaB (NF-κB) transcriptions factor is a major mediator of immune homeostasis and inflammation, and evidence suggested that NF-κB plays a central role in the inflammation response [23]. However, whether LMX1B regulated NF-κB and NLRP3 signal pathway and involved in OA development remains unclear. In the current study, we determined the specific role of LMX1B on cell apoptosis and inflammatory response in IL-1β-induced human osteoarthritis chondrocytes. Our study uncovers the role of LMX1B and its regulation of NF-κB and NLRP3 signal pathway in chondrocytes.

2. Methods

2.1. Patients. Tissue collection in this study was approved by the Ethic Committee of Central Hospital Affiliated to Shenyang Medical Collage (Shenyang) and according to the principles of the Declaration of Helsinki. Human cartilage samples were obtained from 20 osteoarthritis patients (age 58.2 ± 9.8) undergoing total knee arthroplasty and 10 healthy donors (age 55.4 ± 7.6) undergoing total hip replacement surgery because of femoral neck fracture. Moreover, healthy donors do not have arthritis or rheumatoid arthritis. The informed consent form was obtained from all donors. Tissue samples were collected after surgery and stored at -80°C.

2.2. Cell Culture and Treatment. Human chondrosarcoma cell line SW1353 and C28/I2 cells (American Type Culture Collection, Manassas, VA, USA) were maintained in Dulbecco’s modified Eagle medium (DMEM), supplemented with 10% fetal bovine serum in humidified incubated air with 5% CO₂ at 37°C. IL-1β was purchased from the R&D Systems (Abingdon, UK) and dissolved in phosphate-buffered saline (PBS). SW1353 and C28/I2 cells were treated with 10 ng/ml IL-1β to simulate osteoarthritis injury.

2.3. Cell Grouping and Transfection. The SW1353 cells were divided into seven groups: control group, IL-1β group, IL-1β+control siRNA group, IL-1β+LMX1B siRNA group, IL-1β+PDTC group, IL-1β+LMX1B siRNA+pcDNA3.1 group, and IL-1β+LMX1B siRNA+pcDNA3.1-NLRP3 group. The C28/I2 cells were divided into four groups: control group, IL-1β group, IL-1β+control siRNA group, and IL-1β+LMX1B siRNA group. In the IL-1β group, SW1353 and C28/I2 cells were treated with 10 ng/ml IL-1β for 24 h. In the IL-1β+control siRNA group and IL-1β+LMX1B siRNA group, the SW1353 and C28/I2 cells were transfected with control siRNA or LMX1B siRNA for 24 h by using Lipofectamine 2000 reagent and then treated with 10 ng/ml IL-1β for 24 h. In the IL-1β+PDTC group, SW1353 cells were treated with 10 ng/ml IL-1β and PDTC for 24 h. In the IL-1β+LMX1B siRNA+pcDNA3.1-NLRP3 group, SW1353 cells were cotransfected with LMX1B siRNA and pcDNA3.1 control vector or LMX1B siRNA and pcDNA3.1-NLRP3 vector for 24 h and then treated with 10 ng/ml IL-1β for 24 h.

2.4. Cell Viability Assay. SW1353 and C28/I2 cell viability was determined using a Cell Counting Kit-8 (CCK8) assay. Briefly, SW1353 cells were seeded in 96-well plates at a density of 5 × 10³ cells/well for 24 h and then treated and transfected as above. At the appropriate time, CCK8 solution (10 μl) was added to each well then cultured at 37°C for another 4 h. Absorbance at a wavelength of 490 nm was measured and recorded with a microplate reader (Model 680; Bio-Rad, Hercules, CA, USA).

2.5. Cell Proliferation Assay. SW1353 and C28/I2 cell proliferation was determined using 5-ethyl-2'-deoxyuridine (EdU) assay according to the manufacturer’s protocol. SW1353 and C28/I2 cells were seeded in 96-well plates at a density of 2 × 10⁴ cells/well for 24 h and then treated and transfected as above. The cells were treated with 50 μM EdU at 37°C for another 2 h, and cell nuclei were stained with DAPI at room temperature for 15 min. Images were obtained by using an inverted fluorescent microscope.

2.6. Cell Apoptosis. According to the instructions of the manufacturer, Annexin V-APC/7-AAD kit (BD Pharmingen, San Diego, CA, USA) was used to detect cell apoptosis. SW1353 and C28/I2 cells were treated as above. Subsequently, cells from different treatment groups were resuspended in 500 μl of 1× binding buffer, stained with Annexin V-APC (5 μL) and 7-AAD (5 μL) for 15 min in the dark, respectively, and then examined using a flow cytometer (Beckman Coulter, CA, USA).

2.7. Enzyme-Linked Immunosorbent Assay (ELISA). The supernatant from each group was collected, and the concentration of IFN-γ, TNF-α, IL-6, MMP-3, MMP-13, and PGE2 was measured with the appropriate ELISA kit (R&D Systems, Minneapolis, MN USA) according to the manufacturer’s instructions.

2.8. NO Measurement. Griess reaction method was used to detect NO concentrations in the supernatant according to the manufacturer’s instructions. The supernatant was collected from SW1353 and C28/I2 cells which were treated and transfected as mentioned above. An equal volume of cell suspension and Griess reagent was mixed and then incubated for 10 min at room temperature. Absorbance at a wavelength of 550 nm was measured and recorded with a microplate reader (Model 680; Bio-Rad, Hercules, CA, USA).
2.9. **RT-PCR.** Total intracellular RNA from SW1353 and C28/I2 cell was obtained using the TRIzol® Plus RNA Puri-

fication Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. RNA was reverse transcribed to cDNA by using the ThermoScript RT-PCR system (Invitrogen). RT-PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and the ABI prism 7900HT sequence detection system (Applied Biosystems). GAPDH was used as an internal control. Gene expression was calculated by the 2-ΔΔCt method.

2.10. **Western Blot.** Total protein from SW1353 and C28/I2 cell was obtained using radio-immunoprecipitation assay lysis buffer. Protein concentration was quantified using a BCA Protein Assay kit (Beyotime Biotechnology, Shanghai, China). 30 μg of proteins was separated using 10% SDS-PAGE and then transferred onto the PVDF membranes. The membranes were incubated with primary antibodies overnight at 4°C and sequentially incubated with the corresponding secondary antibodies conjugated by horseradish peroxidase (HRP) for 1 h at room temperature. GAPDH

**Figure 1:** LMX1B was upregulated in OA cartilage tissue and IL-1β-induced chondrocytes. (a, c, and e) qRT-PCR analysis for LMX1B mRNA expression in cartilage tissue (a), SW1353 cells (c), and C28/I2 cells (e). (b, d, and f) Western blot analysis for LMX1B protein expression in cartilage tissue (b), SW1353 cells (d), and C28/I2 cells (f). SW1353 and C28/I2 cells were treated with 10 ng/ml IL-1β for 24 h. *P < 0.05. 20 OA patients and 10 normal subjects were used in this study; moreover, all experiments were repeated three times in SW1353 and C28/I2 cells.
was used as a control. The following primary antibodies were used in this study: rabbit polyclonal to LMX1B antibody (ab139736, 1.5 μg/ml), rabbit monoclonal to NLRP3 antibody (ab263899, 1:1000), rabbit monoclonal to p-P65 (ab76302, 1:1000), rabbit monoclonal to NF-κB p65 (ab32536, 1:5000), and rabbit polyclonal to GAPDH (ab9485, 1:2500).
Figure 3: LMX1B knockdown increased IL-1β-induced C28/I2 cell growth and suppressed its apoptosis. (a) Western blot analysis for LMX1B protein expression; (b) CCK-8 analysis for C28/I2 cell survival; (c) 5-ethynyl-2′-deoxyuridine (EdU) assay was used to determine C28/I2 cell proliferation; (d) C28/I2 cell apoptosis was detected by using flow cytometer analysis. C28/I2 cells were transfected with control siRNA or LMX1B siRNA for 24 h by using Lipofectamine 2000 reagent and then treated with 10 ng/ml IL-1β for 24 h. *P < 0.05, compared with the control group; #P < 0.05, compared with the IL-1β group. All experiments were repeated three times.
2.11. Lentivirus Vector Construction. For the following experiments, recombinant lentivirus vectors pCDH-CMV-MCS-EF1-puro expressing LMX1B siRNA and siRNA control were obtained from Genechem (Shanghai, China).

2.12. OA Model in Rats and Animal Treatment. 9-10-week-old male Sprague-Dawley rats (270–285 g) were purchased from the Animal Center of Chinese Academy of Sciences (Shanghai, China) and housed with free access to food and

![Bar graphs](image-url)
water under a 12 h light/dark cycle at room temperature. An animal study in this study was approved by the Animal Care and Use Committee of Central Hospital Affiliated to Shenyang Medical Collage. 28 rats were randomly distributed into four groups: a sham control group (control), an osteoarthritis group (OA), an osteoarthritis treated with control siRNA group (siRNA), and an osteoarthritis treated with LMX1B siRNA group (LMX1B siRNA). Rat knee OA model was established by anterior cruciate ligament transection (ACLT) as described previously [24]. Briefly, the anesthetized rats were made with a parapatellar skin incision on the medial side of the right knee joint; the patella was

**Figure 5**: LMX1B depletion suppressed IL-1β-induced inflammatory cytokines secretion in C28/I2 cells. ELISA kits were used to determine the expression of IFN-γ (a), TNF-α (b), IL-6 (c), and PGE2 (d); (e) NO concentration was determined by the Griess reaction. C28/I2 cells were transfected with control siRNA or LMX1B siRNA for 24 h by using Lipofectamine 2000 reagent and then treated with 10 ng/ml IL-1β for 24 h. *P < 0.05, compared with the control group; **P < 0.05, compared with the IL-1β group. All experiments were repeated three times.
dislocated before the ACL was transected. Rats in the control group received a sham operation, incision in the joint without ACLT. One week after the surgery, rats were intra-articular injected with LMX1B siRNA lentivirus vector \( (1 \times 10^9 \text{ PFU}) \) or control siRNA lentivirus vector \( (1 \times 10^9 \text{ PFU}) \) 2 times per week. After six weeks of treatment, the rats were sacrificed and knee samples were obtained.

2.13. Histological Analysis. Knee samples were fixed with 4% paraformaldehyde, embedded into paraffin, and then cut into 5\( \mu \)m sections using a rotary microtome. The samples were stained with hematoxylin-eosin (HE) and Safranin O and Fast Green.

2.14. Statistical Analysis. Data in the present study were presented as mean \( \pm \) SD from three independent experiments. Statistical analysis was carried out using the GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA) and Statistical Product and Service Solutions (SPSS) 17.0 (SPSS Inc., Chicago, IL, USA). Differences between groups were analyzed using one-way ANOVA with a subsequent post hoc Tukey’s test. \( P < 0.05 \) was considered statistically significant.

3. Results

3.1. Expression of LMX1B Was Upregulated in Cartilage Tissue of OA Patients and IL-1\( \beta \)-Induced Chondrocytes. For investigating the function of LMX1B in OA pathogenesis, we first detected the expression of LMX1B in cartilage tissues of 20 OA patients and 10 normal subjects. Results from the qRT-PCR and western blot assay suggested that LMX1B mRNA and protein levels were significantly increased in OA cartilage tissues against normal control (Figures 1(a) and 1(b)). In the present study, we used 10 ng/ml of IL-1\( \beta \) to simulate the OA environment in human chondrosarcoma

![Figure 6: LMX1B depletion suppressed IL-1\( \beta \)-induced MMP3 and MMP13 expression. ELISA kits were used to determine the expression of MMP3 (a and c) and MMP13 (b and d). SW1353 and C28/I2 cells were transfected with control siRNA or LMX1B siRNA for 24 h by using Lipofectamine 2000 reagent and then treated with 10 ng/ml IL-1\( \beta \) for 24 h. * \( P < 0.05 \), compared with the control group; # \( P < 0.05 \), compared with the IL-1\( \beta \) group. All experiments were repeated three times.](image-url)
increased to 34% and 27.58% in SW1353 and C28/I2 cells, and apoptosis. Moreover, IL-1\( \beta \) results imply a regulatory role of LMX1B depletion on IL-1\( \beta \) knockdown group was 14.8% and 16.29%. These results indicate that LMX1B was increased in OA tissue and cells, and its dysregulate may be involved in OA pathogenesis.

3.2. LMX1B Silence Promoted Cell Growth and Suppressed Cell Apoptosis in SW1353 and C28/I2 Cells. We next sought to investigate whether LMX1B silence mediated SW1353 and C28/I2 cell survival, proliferation, and apoptosis. LMX1B siRNA transfection significantly inhibited LMX1B expression both in SW1353 (Figure 2(a), \( P < 0.05 \)) and C28/I2 (Figure 3(a), \( P < 0.05 \)) cells compared with the IL-1\( \beta \) group. The results of the CCK-8 assay suggested that IL-1\( \beta \) treatment markedly suppressed SW1353 and C28/I2 cell survival, whereas LMX1B knockdown encouraged cell survival in IL-1\( \beta \)-exposed SW1353 (Figure 2(b), \( P < 0.05 \)) and C28/I2 (Figure 3(b), \( P < 0.05 \)) cells. Results from the EdU assay indicated that LMX1B knockdown significantly promoted SW1353 and C28/I2 cell proliferation when compared with the IL-1\( \beta \) group (Figures 2(c) and 3(c), \( P < 0.05 \)). Moreover, IL-1\( \beta \) treatment resulted in cell apoptosis increased to 34% and 27.58% in SW1353 and C28/I2 cells, respectively; moreover, LMX1B knockdown reversed the effects of IL-1\( \beta \) on SW1353 and C28/I2 cell apoptosis (Figures 2(d) and 3(d), \( P < 0.05 \)); cell apoptosis rate in the LMX1B knockdown group was 14.8% and 16.29%. These results imply a regulatory role of LMX1B depletion on IL-1\( \beta \)-induced SW1353 and C28/I2 cell survival, proliferation, and apoptosis.

3.3. LMX1B Is Essential for the Production of Inflammatory Cytokines in IL-1\( \beta \)-Induced SW1353 and C28/I2 Cells. Next, to validate the effects of LMX1B knockdown on the inflammation response in IL-1\( \beta \)-induced chondrocyte, the expression of inflammatory cytokines IFN-\( \gamma \), TNF-\( \alpha \), IL-6, PGE2, and NO was analyzed by the appropriate ELISA kit according to the manufacturer’s instructions. IFN-\( \gamma \), TNF-\( \alpha \), IL-6, PGE2, and NO were all significantly increased after IL-1\( \beta \) treatment compared to the control group (Figures 4 and 5, \( P < 0.05 \)). Additionally, at IL-1\( \beta \)+control siRNA group, IFN-\( \gamma \), TNF-\( \alpha \), IL-6, PGE2, and NO were all almost unchanged compared to the IL-1\( \beta \)-treated group (Figures 4 and 5, \( P > 0.05 \)), and importantly, these inflammatory cytokines were considerably downregulated compared to the IL-1\( \beta \)-treated group and IL-1\( \beta \)+control siRNA group (Figures 4 and 5, \( P < 0.05 \)).

3.4. LMX1B Depletion Plays Important Role in IL-1\( \beta \)-Induced MMP3 and MMP13 Expressions in SW1353 and C28/I2 Cells. In order to assess whether the LMX1B depletion mediated MMP3 and MMP13 expressions in IL-1\( \beta \)-induced SW1353 and C28/I2 cells, ELISA assay was carried out. In fact, stimulation with IL-1\( \beta \) significantly increased the release of MMP3 and MMP13 into the culture medium both in SW1353 (Figures 4(a) and 5(b), \( P < 0.05 \)) and C28/I2 cells (Figures 4(c) and 5(d), \( P < 0.05 \)). Additionally, MMP3 and MMP13 expressions were significantly reduced after LMX1B siRNA transfection as compared with the IL-1\( \beta \) group (Figure 6).

3.5. LMX1B Knockdown Inhibits NF-\( \kappa \)B Activation and Attenuates NLRP3 Expression. To understand the regulatory role of LMX1B, NF-\( \kappa \)B, and NLRP3 signal pathway has been investigated. As shown in Figure 7(a), IL-1\( \beta \) proinflammatory stimulus enhanced NF-\( \kappa \)B signal pathway activation through promoting p-P65 expression, whereas total P65...
**Mediators of Inflammation**

**Figure 8: Continued.**
expression was unchanged. Moreover, IL-1β treatment significantly increased NLRP3 expression, compared with the control group (P < 0.05). Additionally, expression of p-P65 and NLRP3 in the IL-1β+LMX1B siRNA transfection group markedly declined, compared with the IL-1β group (Figure 7(a), P < 0.05). Additionally, we observed that the NF-κB activation and NLRP3 expression showed a tight positive correlation in SW1353 cells treated with IL-1β. Results from western blot assay showed that the inhibitor of NF-κB signal pathway reversed the effects of IL-1β on the expression of NLRP3 (Figure 7(b)). The above results indicated that LMX1B silence inhibited NLRP3 expression which may be through inhibiting NF-κB activation.

3.6 NLRP3 Overexpression or NF-κB Activation Restrained the Effects of LMX1B Silence on SW1353 Cell Biology. To investigate the effects of NF-κB and NLRP3 signal pathway on the action of LMX1B silence in IL-1β-induced SW1353 cells, we used NF-κB activator LPS (400 μg/ml) and engineered NLRP3 overexpression plasmids for restoring the expression of p-P65 and NLRP3. As shown in Figures 8(a) and 8(b), NF-κB activation and LMX1B overexpression significantly suppressed cell survival and proliferation compared with the LMX1B knockdown group (P < 0.05). We also examined the influence of LPS and LMX1B overexpression vector on cell apoptosis, inflammatory cytokines, and MMP3 and MMP13 expression in LMX1B silence and IL-
1β-induced SW1353 cells. Cell apoptosis, IFN-γ, TNF-α, IL-6, PGE2, NO, MMP3, and MMP13 expressions were augmented significantly after exposure to LPS and transfecting with LMX1B overexpression vector, compared with LMX1B knockdown group \((P < 0.05)\). These results indicated that LMX1B silence plays effective roles in cell apoptosis and inflammatory response dependent on NF-κB and NLRP3 signal pathway.

3.7. LMX1B Depletion Suppressed Pathogenesis of Osteoarthritis in Sprague-Dawley Rats. We next assessed whether LMX1B depletion plays roles in the regulation of OA cartilage destruction. Lentiviruses with LMX1B siRNA were injected into the knee joints of OA rats. Hematoxylin and eosin (HE) and Safranin O staining were performed. In the results as shown in Figure 9, compared with the control group, OA group rats exhibited osteoarthritis characteristics.
with severely degraded cartilage and clear hypocellularity. Moreover, we observed that LMX1B depletion significantly alleviated symptoms of OA (Figure 9). Moreover, IFN-γ, TNF-α, IL-6, PGE2, and NO levels were already significantly increased in OA rats, and these inflammatory cytokines were considerably downregulated after LMX1B depletion (Figures 10(a)–10(e), \( P < 0.05 \)). These data indicated that LMX1B depletion had protective effects in vivo.

4. Discussion

Osteoarthritis (OA) is a highly prevalent chronic disorder of joints featuring degeneration of articular cartilage. Up to now, treatment of osteoarthritis remains a difficult problem, and although physical therapy and pain medications are used, there have been limited effects and significant side effects [1, 25]. The present study firstly provided evidence that LMX1B knockdown plays significant effect roles in the pathogenesis of OA. Firstly, we found that LMX1B expression presented a significant elevation in OA patients’ tissues and IL-1β-induced human chondrocytes. Secondly, we observed that LMX1B silence promoted cell survival and proliferation and suppressed cell apoptosis and inflammatory response in IL-1β-induced human osteoarthritis chondrocytes. Thirdly, we demonstrated that NF-κB/NLRP3 signal pathway plays an irreplaceable role in the action of LMX1B depletion in IL-1β-induced chondrocytes. Finally, we used OA model in Sprague-Dawley rats to confirm the protective effects of LMX1B silence against OA. Based on our data, we suggested that LMX1B might play an important role in the progression of OA.

LMX1B proteins are a member of the transcription factor family which is stimulated by chemokine, extracellular matrix (ECM) degradation products, stress-related factors, and proinflammatory cytokines [36]. A recent study also suggested that the expression of the NLRP3 inflammasome was accompanied by the activation of Toll-like receptors (TLRs) and NF-κB [37]. In the present study, we confirmed that NF-κB inhibitor suppressed NLRP3 expression. In addition, evidence suggested that NLRP3 contributed to inflammatory cytokine production [38]. Moreover, recent studies indicated that NLRP3 was a potentially novel biomarker of OA and might play essential roles in the pathogenesis of OA [39, 40]. In the current study, we observed that LMX1B depletion suppressed NF-κB-p65 activation and NLRP3 expression, and NF-κB-p65 activation and NLRP3 overexpression both reversed the effects of LMX1B knockdown on chondrocytes apoptosis and inflammation.

5. Conclusion

Collectively, the present study provided the first evidence that LMX1B knockdown exerts protective activity in IL-1β-induced human chondrocytes and OA model. Also, the possible mechanisms of LMX1B knockdown in IL-1β-induced chondrocytes might involve the inactivation of NF-κB and the inhibition of NLRP3. In summary, LMX1B knockdown may be effective in the treatment of OA.

Data Availability

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

References

[1] J. Chen, Y. Gu, J. Xie et al., “Gastrodin reduces IL-1β-induced apoptosis, inflammation, and matrix catabolism in osteoarthritis chondrocytes and attenuates rat cartilage degeneration in vivo,” Biomedicine & Pharmacotherapy, vol. 97, pp. 642–651, 2018.

[2] W. Tong, Y. Geng, Y. Huang et al., “In vivo identification and induction of articular cartilage stem cells by inhibiting NF-κB signaling in osteoarthritis,” Stem Cells, vol. 33, no. 10, pp. 3125–3137, 2015.

[3] D. Wan, Y. Qu, S. Ai, and L. Cheng C, “miR-152 attenuates apoptosis in chondrocytes and degeneration of cartilages in osteoarthritis rats via TCF-4 pathway,” Dose Response, vol. 18, no. 4, article 155932582094691, 2020.

[4] C. R. Scanzello and S. R. Goldring, “The role of synovitis in osteoarthritis pathogenesis,” Bone, vol. 51, no. 2, pp. 249–257, 2012.

[5] D. P. Page Thomas, B. King, T. Stephens, and J. T. Dingle, “In vivo studies of cartilage regeneration after damage induced by catabolin/interleukin-1,” Annals of the Rheumatic Diseases, vol. 50, no. 2, pp. 75–80, 1991.
[6] B. Henderson and E. J. C. Pettipher, “Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo,” *Clinical and Experimental Immunology*, vol. 75, no. 2, pp. 306–310, 1989.

[7] J. Jiang, J. Zhang, C. Wu et al., “Up-regulation of TRAF2 inhibits chondrocytes apoptosis in lumbar facet joint osteoarthritis,” *Biochemical and Biophysical Research Communications*, vol. 503, no. 3, pp. 1659–1665, 2018.

[8] O. Bruyère, G. Honvo, N. Veronese et al., “An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO),” *Seminars in Arthritis and Rheumatism*, vol. 49, no. 3, pp. 337–350, 2019.

[9] X. Zhou, J. Li, Y. Zhou et al., “Down-regulated ciRS-7/up-regulated miR-7 axis aggrassed cartilage degradation and autophagy defection by PI3K/AKT/mTOR activation mediated by IL-17A in osteoarthritis,” *Aging (Albany NY)*, vol. 12, no. 20, pp. 20163–20183, 2020.

[10] X. Yan, J. Lin, Y. Wang et al., “A novel small deletion of LMX1B in a large Chinese family with nail-patella syndrome,” *BMC Medical Genetics*, vol. 20, no. 1, p. 71, 2019.

[11] L. Fan, A. Zhang, and P. J. B. Deng, “LMXB1 mRNA expression and its gene body CpG methylation are valuable prognostic biomarkers for laryngeal squamous cell carcinoma,” *Biomedicine & Pharmacotherapy*, vol. 117, p. 109174, 2019.

[12] R. Morello, G. Zhou, S. Dreyer et al., “Regulation of glomerular basement membrane collagen expression by LMX1B contributes to renal disease in nail-patella syndrome,” *Nature Genetics*, vol. 27, no. 2, pp. 205–208, 2001.

[13] Y. Ding, J. Yin, A. Kania, Z. Q. Zhao, R. L. Johnson, and Z. F. Chen, “Lmx1b controls the differentiation and migration of the superficial dorsal horn neurons of the spinal cord,” *Development*, vol. 131, no. 15, pp. 3693–3703, 2004.

[14] C. Asbreuk, C. Vogelaar, A. Hellemans, M. P. Smidt, and J. P. Burbach, “CNS expression pattern of Lmx1b and coexpression with ptx genes suggest functional cooperativity in the development of forebrain motor control systems,” *Molecular and Cellular Neurosciences*, vol. 21, no. 3, pp. 410–420, 2002.

[15] H. Chen, Y. Lun, D. Ovchinnikov et al., “Limb and kidney defects in Lmxb1 mutant mice suggest an involvement of LMX1B in human nail patella syndrome,” *Nature Genetics*, vol. 19, no. 1, pp. 51–55, 1998.

[16] C. Pressman, H. Chen, and R. J. G. Johnson, “LMXB1, a LIM homeodomain class transcription factor, is necessary for normal development of multiple tissues in the anterior segment of the murine eye,” *Genesis*, vol. 26, no. 1, pp. 15–25, 2000.

[17] M. Smidt, C. Asbreuk, J. Cox, H. Chen, R. L. Johnson, and J. P. H. Burbach, “A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b,” *Nature Neuroscience*, vol. 3, no. 4, pp. 337–341, 2000.

[18] A. Kania, R. Johnson, and T. J. C. Jessell, “Coordinate roles for LIM homeobox genes in directing the dorsoventral trajectory of motor axons in the vertebrate limb,” *Cell*, vol. 102, no. 2, pp. 161–173, 2000.

[19] T. Zhou, H. Xu, Y. Qiu, F. Y. Lei, W. F. Huang, and G. P. C. Drummen, “LIM homeobox transcription factor 1B is associated with pro-fibrotic components and apoptosis in hypoxia/reoxygenation renal tubular epithelial cells,” *Apoptosis*, vol. 19, no. 4, pp. 594–602, 2014.

[20] N. Li, H. Zhou, H. Wu et al., “STING-IRF3 contributes to lipopolysaccharide-induced cardiac dysfunction, inflammation, apoptosis and pyroptosis by activating NLRP3,” *Redox Biology*, vol. 24, p. 101215, 2019.

[21] M. Takahashi, “Role of NLRP3 inflammasome in cardiac inflammation and remodeling after myocardial infarction,” *Biological & Pharmaceutical Bulletin*, vol. 42, no. 4, pp. 518–523, 2019.

[22] Y. He, H. Hara, and G. Núñez, “Mechanism and regulation of NLRP3 inflammasome activation,” *Trends in Biochemical Sciences*, vol. 41, no. 12, pp. 1012–1021, 2016.

[23] D. Kulms and T. Schwarz, “NF-κB and cytokines,” *Vitamins and Hormones*, vol. 74, pp. 283–300, 2006.

[24] G. Zhen, C. Wen, X. Jia et al., “Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis,” *Nature Medicine*, vol. 19, no. 6, pp. 704–712, 2013.

[25] F. Jakob, F. Genest, G. Baron, U. Stumpf, M. Rudert, and L. Seefried, “Regulation of bone metabolism in osteoporosis: novel drugs for osteoporosis in development,” *Unfallchirurg*, vol. 118, no. 11, pp. 925–932, 2015.

[26] T. Dunston, J. Hamlington, J. Zaveri et al., “The human LMX1B gene: transcription unit, promoter, and pathogenic mutations,” *Genomics*, vol. 84, no. 3, pp. 565–576, 2004.

[27] C. Iannotti, H. Inoue, E. Bernal et al., “Identification of a human LMX1 (LMX1.1)-related gene, LMX1.2: tissue-specific expression and linkage mapping on chromosome 9,” *Genomics*, vol. 46, no. 3, pp. 520–524, 1997.

[28] S. Dreyer, G. Zhou, A. Baldini et al., “Mutations in LMX1B cause abnormal skeletal patterning and renal dysplasia in nail-patella syndrome,” *Nature Genetics*, vol. 19, no. 1, pp. 47–50, 1998.

[29] D. Vollrath, V. Jaramillo-Babb, M. Clough et al., “Loss-of-function mutations in the LIM/homeodomain gene, LMX1B, in nail-patella syndrome,” *Human Molecular Genetics*, vol. 7, no. 7, pp. 1091–1098, 1998.

[30] A. Rasche, T. Neumann, A. Raschta et al., “The LIM-homeodomain transcription factor LMX1B regulates expression of NF-κappa B target genes,” *Experimental Cell Research*, vol. 315, no. 1, pp. 76–96, 2009.

[31] C. Zang, F. Zhao, and Y. Pu, “LMXB1 involved in the radioreistance, proliferation and migration of esophageal cancer cells,” *Biomedicine & Pharmacotherapy*, vol. 118, p. 109358, 2019.

[32] T. Zhou, C. Ou, Y. Qiu, F. Y. Lei, W. F. Huang, and G. P. C. Drummen, “LIM homeobox transcription factor 1B expression affects renal interstitial fibrosis and apoptosis in unilateral ureteral obstructed rats,” *American Journal of Physiology. Renal Physiology*, vol. 306, no. 12, pp. F1477–F1488, 2014.

[33] P. Wojdasiewicz, L. A. Poniatowski, and D. Szukiewicz, “The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis,” *Mediators of Inflammation*, vol. 2014, 19 pages, 2014.

[34] M. Goldring, M. Otero, and D. Plumb, “Roles of inflammatory and anabolic cytokines in cartilage metabolism: signals and multiple effectors converge upon MMP-13 regulation in osteoarthritis,” *European Cells & Materials*, vol. 21, pp. 202–220, 2011.

[35] P. Garnero and J. Rousseau, “Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases,” *Arthritis and Rheumatism*, vol. 43, no. 5, pp. 953–968, 2000.
[36] S. Rigoglou and A. G. Papavassiliou, “The NF-κB signalling pathway in osteoarthritis,” The International Journal of Biochemistry & Cell Biology, vol. 45, no. 11, pp. 2580–2584, 2013.

[37] Y. Li, W. Liang, C. Guo et al., “Renshen Shouwu extract enhances neurogenesis and angiogenesis via inhibition of TLR4/NF-κB/NLRP3 signaling pathway following ischemic stroke in rats,” Journal of Ethnopharmacology, vol. 253, p. 112616, 2020.

[38] X. Qu, H. Gao, L. Tao et al., “Astragaloside IV protects against cisplatin-induced liver and kidney injury via autophagy-mediated inhibition of NLRP3 in rats,” The Journal of Toxicological Sciences, vol. 44, no. 3, pp. 167–175, 2019.

[39] A. Fioravanti, S. Tenti, M. McAllister et al., “Exploring the involvement of NLRP3 and IL-1β in osteoarthritis of the hand: results from a pilot study,” Mediators of Inflammation, vol. 2019, 11 pages, 2019.

[40] Y. Sun, W. Liu, H. Zhang et al., “Curcumin prevents osteoarthritis by inhibiting the activation of inflammasome NLRP3,” Journal of Interferon & Cytokine Research, vol. 37, no. 10, pp. 449–455, 2017.